



INCIDENCE, SEVERITY AND IMPACT OF INFLUENZA

16-18 JANUARY 2019
STOCKHOLM



PROGRAMME

DAY 1 Wednesday 16 January

09:30 – 10:30 Registration / Poster mounting

11:00 – 11:30 Welcome Address

Barbara Rath & Pasi Penttinen ISIRV and ECDC meeting chairs

11:30 – 13:00 Key Methodological Challenges

Mike Catchpole (ECDC)

The need and use of Influenza risk assessments in EU

Katelijan Vandemaele (WHO)

Pandemic Influenza Severity Assessment as a tool to guide public health decision-making globally

Danielle Iuliano (US CDC)

Improving estimation of the global burden of influenza hospitalizations and mortality

13:00- 14:00 LUNCH

14:00 – 15:00 Defining challenges / expectations

Small group breakout sessions– each with a focus on 1 of **6 key topics**

- 1 Linking clinical research and surveillance
- 2 What happens outside the hospital?
- 3 Learning from real-world clinical and patient data
- 4 Predicting outcomes on the individual and population level
- 5 Advancing public health surveillance of severity
- 6 Surveillance of severity in low resource or crowded settings

15:00 - 16:00 ORAL SESSION 1

Jolita Mereckiene - Health Protection Surveillance Centre, Dublin, Ireland

Seasonal influenza vaccination recommendations, vaccination coverage and payment mechanisms in EU EEA countries, between 2008-09 and 2017-18 influenza season. Results from surveys conducted by the VENICE network

Md Ariful Islam - International Centre for Diarrhoeal Disease and Research, Bangladesh (icddr,b)

Post-discharge mortality among patients hospitalized with severe acute respiratory infection in Bangladesh, 2011- 2018

Henry Laurenson-Schafer - World Health Organization

A tool to set thresholds on influenza surveillance data

Toomas Timpka – Lingöping University, Sweden

Real-time nowcasting (integrated detection and prediction) of influenza epidemics in local settings: prospective evaluation in Östergötland County, Sweden

Dwi Agustian - Universitas Padjadjaran

Geographical Clustering of Human Influenza A Virus Infections in Two Communities in Indonesia

16:00 - 16:30 Coffee Break

16:30 - 18:00 Scientific Committee Members

Reporting back on the 6 key topics - Panel discussion.

18:00 + Poster Reception & Poster Presentations

DAY 2 Thursday 17 January

08:30 – 10:00 TOPIC 1 Linking clinical research and surveillance networks

Chair | Gail Carson

1.1 Gail Carson (Univ Oxford, UK, ISARIC)

Clinical research networks: recent advances

1.2 Benjamin Cowling (Univ Hong Kong; ISIRV)

Transmission dynamics at the individual level with disease burden, severity and dynamics at the population level

1.3 Deepali Kumar (Univ. Toronto)

Influenza disease severity in high-risk and transplant populations

10:00 – 10:30 Coffee Break + Poster Viewing

10:30 – 12:00 TOPIC 2 What happens outside the hospital?

Chair | Tim Uyeki

2.1 Tim Uyeki (US CDC)

What are the gaps in current knowledge on influenza severity outside the hospital?

2.2 Jesus Castilla (Instituto de Salud Pública, Navarra)

Detection of influenza and other respiratory viruses in deceased persons swabbed in funeral parlours, Navarra, Spain

2.3 Andrew Hayward (University College London, UK)

The spectrum of influenza virus infection in the community – findings of the UK Flu Watch study.

12:00 - 12:30 SESSION 2 Oral presentations on Topics 1 and 2

12:00 - 12:15 Siri Helene Hauge (Norwegian Institute of Public Health)

Medically attended influenza like illness in Norway, 2008-17

12:15 - 12:30 Edgar Mojica (Universidad Nacional Autonoma De Mexico)

Use of space-time cubes to detect influenza patterns in Mexico

12:30 - 13:30 LUNCH

13:30 – 15:00 TOPIC 3 Learning from real-world clinical and patient data

Chair | Barbara Rath

3.1 Barbara Rath (ViVI, Germany/USA; ISIRV)

Partnering for Enhanced Digital Surveillance of Influenza Disease and the Effect of Antivirals and Vaccines (PEDSIDEA)

3.2 Daniela Paolotti (ISI Foundation, Italy)

Influenza and self-reporting: modelling challenges in participatory surveillance

3.3 Elektra Papadopoulou (FDA, US)

Clinical Outcomes Assessment: measuring vaccine and drug effectiveness

15:00 - 15:30 Coffee Break + Poster Viewing

15:30 – 17:00 TOPIC 4 Predicting outcomes on the individual and population level

Chair | Yuelong Shu

4.1 Yuelong Shu (School of Public Health Shenzhen, China)

Predicting disease severity using biomarkers

4.2 Matt Biggerstaff (US CDC)

Forecasting influenza in the United States

4.3 Gideon Emukule (CDC Kenya)

Burden of severe influenza disease in the context of competing priorities in Sub-Saharan Africa

17:00 - 17:30 SESSION 3 Oral Presentations on Topics 3 and 4

17:00 - 17:15 George Milne (University of Western Australia)

Population-wide effectiveness of enhanced influenza vaccines use for Older Adults

17:15 - 17:30 Mohamed Elhakim (World Health Organization, EMRO, Egypt)

Severe cases of influenza reported to EMFLU Network in the Eastern Mediterranean Region of WHO, influenza seasons 2016/17 and 2017/18

DAY 3 Friday 18 January

08:30 – 10:00 TOPIC 5 Advancing public health surveillance of severity

Chair | Pasi Penttinen

5.1 Pasi Penttinen (ECDC)

Surveillance of influenza severity in EU, (EuroMomo, iMove, ICU surveillance); lessons learnt and needs for the future

5.2 Carrie Reed (US CDC)

Burden, Incidence and prescriptions: The CDC's approach to population-based severity assessment burden estimates

5.3 Cheryl Jones (Univ Melbourne, Australia)

Assessing non-respiratory complications of influenza disease – the Australian PAEDS System

10:00 - 10:30 Coffee Break + Poster Viewing

10:30 – 12:00 TOPIC 6 What happens outside the hospital?

Chair | Cheryl Cohen

6.1 Cheryl Cohen (National Institute for Communicable Diseases, South Africa)

Conducting epidemiological research in underserved and vulnerable populations (incl. HIV/AIDS)

6.2 Ziad Memish (Prince Mohammed bin Abdulaziz Hospital, Saudi Arabia)

Mass gatherings and the epidemiology of acute respiratory viral infections: an overview of the literature

6.3 Alice Wimmer (International Organisation for Migration, UN)

Ensuring migrant inclusion in National Pandemic Influenza Preparedness Plans

12:00 - 12:30 SESSION 4 Oral Presentations on Topics 5 and 6

12:00 - 12:15 Jean-Michel Heraud (Institut Pasteur de Madagascar)

Assessing severity and impact of influenza in Madagascar: insight from biological surveillance to mortality data and economic burden.

12:15 - 12:30 Jens Nielsen (Statens Serum Institut)

European all-cause excess and influenza-attributable mortality in the 2017/2018 season: Should the burden of influenza B be reconsidered?

12:30 - 13:30 Closing Statements

Julia Fitzner (WHO): Take-away messages

Barbara Rath (ISIRV) & Pasi Penttinen (ECDC):

Needs Statement - Planning next steps incl. joint publications
